WHO/HIVResNet HIV Drug Resistance Laboratory Operational Framework. WHO. (2017)

immage
The WHO/HIVResNet Laboratory Operational Framework describes how WHO HIVResNet laboratories function to support national, regional, and global HIV drug resistance (HIVDR) surveillance by providing accurate genotyping results in a standardized format according to WHO specifications.
 

Keywords: HIV, laboratory services, drug resistance
 
 

Issue Brief: Using Competition Law to Promote Access to Medicines and Related Health Technologies in Low- and Middle-income Countries. UNDP. (2017)

immage

Competition law is an important policy tool that LMICs can use to protect consumer welfare and promote industrial and economic development. It aims to restrict unfair business practices, and promote quicker introduction and increased availability of health technologies. The issue brief highlights key aspects of using competition law to promote access to health technologies from UNDP’s landmark publication “Using Competition Law to Promote Access to Health Technologies: A guidebook for low- and middle-income countries.” The issue brief intends to be a resource for policymakers, national competition authorities, national procurement agencies, health authorities, civil society and other actors who have an interest in understanding the critical role of competition authorities in promoting access to health technologies.

 

Keywords: HIV, TB, LMICs, access, medicines, laws

 

Download Publication

The Journey of Universal Access to Antiretroviral Treatment in Thailand. UNDP, Ministry of Public Health and National Health Security Office. (2017)

immage

This book represents the consolidated knowledge and experience related to the policies and management of universal access to ART in Thailand. It aims to serve as an important tool to share knowledge with and advocate the policy of universal health coverage (UHC) to policymakers in the other developing nations that are working towards achieving UHC inclusive of the continuum of HIV and AIDS care services

 

Keywords: Thailand, HIV, PLHIV, ART, treatment, health system

 

 

Download Publication 

Regional Action Plan for Viral Hepatitis in South-East Asia, 2016–2021. WHO, Regional Office for South-East Asia. (2017)

immage

Viral hepatitis now ranks as the seventh leading cause of mortality worldwide. Although mortality due to communicable diseases has declined globally, the absolute burden and relative ranking of viral hepatitis as a cause of mortality has increased between 1990 and 2013.

 

Viral hepatitis causes at least as many, if not more, deaths annually compared with TB, AIDS, or malaria. Mortality due to viral hepatitis is increasing with time, while that due to TB, HIV and malaria is declining. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for more than 90% of viral hepatitis-related deaths and disability, with hepatitis A and E being responsible for the remaining.

 


Keywords: HIV, TB, hepatitis, viral, prevention and control, public health, vaccination

 

Download Publication

What New in Treatment Monitoring: Viral Load and CD4 Testing. WHO. (2017)

immage

Monitoring of individuals on ART is important to ensure treatment efficacy and improved health outcomes.

The 2016 WHO Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection include recommendations on routine monitoring and the diagnosis of treatment failure.

 

Keywords: HIV, ART, CD4, treatment, testing, monitoring

 

 

Download Publication

The Maternal Health Thematic Fund: Towards Equality in Access, Quality of Care and Accountability. UNFPA. (2017)

immage

This report highlights the key results achieved over Phase II of the MHTF, from 2014 to 2016, structured around the three cross-cutting principles of accountability, equality of access and quality of care, as outlined in the MHTF Business Plan Phase II (2014-2017). The report foregrounds the MHTF’s role in supporting health systems strengthening, and addresses its catalytic nature, its promotion of sustainability and its strong emphasis on advancing innovation.


Keywords: health care, women, girls, human rights, gender

 

Download Publication

Transition to New Antiretrovirals in HIV Programmes: Clinical and Programmatic Considerations. WHO. (2017)

immage

WHO has recommended adopting drug regimens with high potency, lower toxicity, high genetic barriers to resistance, usefulness across different populations and lower cost. The use of optimized drug regimens can improve the durability of the treatment and quality of care of people living with HIV.

Adopting optimized antiretroviral (ARV) drug regimens can significantly affect the speed at which the 90 –90 –90 targets are achieved, enhancing access to treatment and improving treatment outcomes with impact on treatment adherence, viral suppression and the quality of life of people living with HIV, reducing pressures on health systems and the risk of HIV transmission.


Keywords: HIV, ARV, drugs, TB, treatment

 

Download Publication

Public Health and HIV Viral Load Suppression. UNAIDS. (2017)

immage

The primary purpose of antiretroviral therapy is to keep people living with HIV in good health. In the large majority of people living with HIV, antiretroviral medication can be chosen that reduce the amount of HIV in the blood to levels that are undetectable by standard laboratory tests. It can take some months to reduce viral levels to undetectable levels and allow the immune system to begin to recover.

 


Keywords: HIV, PLHIV, treatment, health services

 

Download Publication

Key Considerations for Differentiated Antiretroviral Therapy Delivery for Specific Populations: Children, Adolescents, Pregnant and Breastfeeding Women and Key Populations. WHO. (2017)

immage

This document provides key considerations on when clinically stable children, adolescents and women who are pregnant or breastfeeding as well as members of key populations (people who inject drugs, sex workers, men who have sex with men, transgender people and people living in prisons and closed settings) can benefit from access to ART services for clinically stable clients, including less frequent clinic visits and multi-month refills for ART and other medications. The guidance provides the rationale and the approach to expand differentiated ART delivery to populations of people living with HIV who previously may not have been considered “eligible” for ART delivery models for clinically stable clients.

 

Keywords: HIV, ART, treatment, health care

 

Download Publication

Factsheet: Unitaid and Hepatitis C in the Context of Co-infection with HIV. UNITAID. (2017)

immage

According to the WHO, about 2.3 million people are co-infected with HIV and the hepatitis C virus (HCV). Moreover, there were an estimated 1.75 million new hepatitis C virus (HCV) infections worldwide in 2015. HCV usually presents only mild symptoms, if any, until it is at an advanced stage, thereby making it difficult to recognize the disease early.


Keywords: HIV, HCV, diagnosis, treatment

 

 

Download Publication

Pages

Data Dashboard
database
Highlighted publications
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-young-peoples-participation-in-community-based-responses-to-hiv_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNODC_factsheet_Ending_AIDS_by_2030_for_people_and_with_PUD_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_GAP_progress_report_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/HRI-women-harm-reduction-2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Elective_C-section_should_not_be_routinely_recommended_to_WLHIV_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/ESCAP_Asia_and_the_Pacific_SDG_Progress_Report_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guideline_on_digital_interventions_for_health_system_strengthening_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Progress_report_on_HIV_viral_hepatitis_and_STI_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_HIV_UHC_Guide_Civil_Society_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NSACP_Sri_Lanka_Annual_Report_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_HIV-related-travel-restrictions-explainer_2019.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/HIV-and-the-Law-supplement-2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_IBBS_and_Population_size_estimates_among_FSW_2015.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Global_TB_Report_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal_National_Community_Led_HIV_Testing_Guidelines_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_IBBS_PWID_PWUD_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_IBBS_FEW_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/DataHub_TB-HIV_Fact_Sheet_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NSACP_Sri_Lanka_National_HIV_Communication_Strategy_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Status_of_National_AIDS_Response_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V1_North-East_region_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V2_West_South_region_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V3_Northern_Central_Eastern_region_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Annual_report_2016-17.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_for_Managing_Advanced_HIV_Disease_and_Rapid_Initiation_of_ART_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_Estimations_and_projections_of_HIV_AIDS_at_Sub-national_level_2016-2020.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_HIV_drug_resistance_report_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_on_public_health_response_to_pretreatment_HIV_drug_resistance_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_National_Strategic_Plan_on_HIV_and_AIDS_2016-2020.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
Calendar of events
Sep
17
(17 Sep - 17 Sep)
Oct
11
Nov
14